等待开盘 11-18 09:30:00 美东时间
+0.062
+0.13%
Liquidia Corporation will report its third quarter 2026 financial results on November 10, 2026, and host a live webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. The webcast will be available on Liquidia’s website and archived for one year. The company focuses on developing treatments for respiratory and vascular diseases using its proprietary PRINT® Technology, including YUTREPIA® for pulmonary arterial hyp...
11-03 13:30
Liquidia (LQDA) shares jumped 42% after the company reached a $380.7M settlement with United Therapeutics (UTHR), resolving six ongoing lawsuits and securing continued commercialization of YUTREPIA fo...
10-14 13:06
Liquidia Corporation and United Therapeutics Corporation have reached a global settlement resolving all six ongoing lawsuits. YUTREPIA® for PAH patients remains available. Liquidia will pay $380.7 million in installments by 2027. Q3’26 YUTREPIA sales were $222.7 million, with $396.1 million in cash. Liquidia will continue advancing YUTREPIA and L606 programs.
10-13 21:44
Liquidia Technologies ( ($LQDA) ) has provided an announcement. On September 3,...
09-03 20:51
As investors continue to assess the direction of interest rates and the outlook for the U.S. Treasury market, exchange-traded funds offer a relatively low-cost way to gain exposure across different ma...
08-24 21:15
Liquidia 的 2026 年第二季度业绩电话会议涵盖了 YUTREPIA 达 1.704 亿美元的销售额、31% 的季度增长、利润上升、管线支出及其 2027 年目标。
08-14 08:27
An announcement from Liquidia Technologies ( ($LQDA) ) is now available. Liquid...
05-11 19:21
Liquidia Corp (LQDA) reported mixed Q4 results, with earnings missing estimates but sales beating expectations. Analysts have mixed opinions on stock.
03-07 00:17